Novavax vaccine 96% effective against original coronavirus, 86% vs British variant

ReutersPublished: Mar 12, 2021 2:32 AM | Updated: Mar 12, 2021 2:40 AM

Novavax Inc’s Covid-19 vaccine was 96% effective in preventing cases caused by the original version of the coronavirus in a late-stage trial conducted in the United Kingdom, the company said on Thursday, moving it a step closer to regulatory approval.

There were no cases of severe illness or deaths among those who got the vaccine, the company said, in a sign that it could stop the worse effects of new variants that have cropped up.

Beijing dismisses alleged Chinese hacking of Indian vaccine makers

Chinese hackers target Indian vaccine makers SII, Bharat Biotech, says security firm

AstraZeneca, Sputnik vaccines face hurdles if Covid shots become annual affair

COMMENT | Covid-19 vaccines: In God we trust, all else we audit

EU adds anti-variant clauses to new Covid vaccine supply deals: Sources

COMMENT | Another perspective on the 'new' versus 'old' Covid-19 vaccines

Johnson & Johnson's single dose vaccine is up to 72pct effective

Novavax says Covid-19 vaccine is 89.3 percent effective in UK trial

Comments0

By posting a comment, you agree to our Commenting Terms and Conditions as stipulated in full here.

Do's and don'ts when posting comments in Malaysiakini

TERMS & CONDITIONS

Foul language, profanity, vulgarity, slanderous, personal attack, threatening, sexually-orientated comments or the use of any method of communication that may violate any law or create needless unpleasantness will not be tolerated. Antisocial behaviour such as "spamming" and "trolling" will be suspended. Violators run the risk of also being blocked permanently.

REPORT VIOLATORS

Please use the report feature that is available below each comment to flag offending comments for our moderators to take action. Do not take matters in your own hands to avoid unpleasant and unnecessary exchanges that may result in your own suspension or ban.

NOTICE

Our commenting system is still under development. We have taken note of feedback provided.

Subscriber-only space: